Bictegravir
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Bictegravir: From HIV Infection to Simian Immunodeficiency Virus Infection
One-Sentence Summary
Bictegravir is an integrase inhibitor originally used to treat HIV infection and AIDS. The TxGNN model predicts it may be effective for simian immunodeficiency virus (SIV) infection, but there are no registered clinical trials and only 3 publications (in vitro, structural and animal-model work), so this is essentially a preclinical model of the already-approved HIV indication rather than a new human use.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | HIV infectious disease; AIDS (the Singapore licence record contains no indication text) |
| Predicted New Indication | Simian immunodeficiency virus infection |
| TxGNN Prediction Score | 99.82% |
| Evidence Level | L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data are not available in the data compiled for this report. Bictegravir is known to be an integrase strand transfer inhibitor (INSTI) used against HIV-1. SIV is a lentivirus closely related to HIV, and its integrase is structurally similar to the HIV enzyme.
Laboratory work shows that bictegravir is active against SIVmac239, including some INSTI-resistant variants. Structural studies of HIV and SIV integrase complexes support a shared inhibitor binding mode. This explains the very high prediction score.
However, SIV infection is a primate model of the approved HIV indication, not a distinct human disease. Its value lies in preclinical testing of antiviral strategies, not in expanding the human label. Other high-scoring predictions (feline AIDS, hepatitis A/C/E, Omsk hemorrhagic fever and a rare neurodevelopmental disorder) lack a plausible integrase-based rationale and are likely knowledge-graph artifacts.
Clinical Trial Evidence
Currently no related clinical trials registered for SIV infection.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 28923862 | 2017 | In vitro study | Antimicrob Agents Chemother | Antiviral activity of bictegravir and cabotegravir against INSTI-resistant SIVmac239 and HIV-1 |
| 39559349 | 2024 | Preclinical animal model | Front Immunol | Dual-purpose humanized mouse model for testing antiviral strategies against both SIV and HIV |
| 32506843 | 2021 | Review (structural biology) | FEBS J | HIV/SIV intasome structures clarify integrase inhibitor binding and viral escape mechanisms |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN15604P | BIKTARVY FILM-COATED TABLETS 50MG/200MG/25MG | Film-coated tablet | Not stated in the licence record |
Safety Considerations
- Drug Interactions: 81 interactions were identified in total; the main ones are listed below.
- Major: polyvalent cation-containing products, including aluminum hydroxide, magnesium salts (carbonate, chloride, citrate), magaldrate, calcium salts (acetate, carbonate, citrate, glubionate, gluconate, lactate, phosphate), iron, kaolin and attapulgite. These are generally expected to reduce integrase inhibitor absorption, so dose timing should be reviewed.
- Moderate: aprepitant, clarithromycin, dexamethasone, eliglustat and glycerol phenylbutyrate.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: SIV infection is a veterinary/preclinical model of the approved HIV indication, so it offers little human repurposing value. Evidence is limited to in vitro, structural and animal-model work, with no clinical trials. Bictegravir is already marketed in Singapore for its original HIV use.
To proceed, the following is needed:
- Detailed mechanism-of-action data
- Package insert warnings and contraindications from the HSA record
- A defined human or translational research question; the more meaningful lead in this candidate list is perinatal HIV (pregnancy exposure cohort data, L3), which merits separate assessment
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.